InMed Reports Pre-Clinical Study Results for its Leading Product INM-750

InMed Pharmaceuticals (OTCMKTS:IMLFF) provided an update on the progress of its lead product INM-750 for epidermolysis bullosa (EB), a serious and severe genetically inherited skin disorder. The company reported that INM-750 has demonstrated positive effects in pre-clinical studies on wound healing and in inflammation.
As quoted in the press release:

INM-750 is a topical formulation of phytocannabinoids that have been carefully selected using our proprietary bioinformatics discovery platform to treat: (i) the underlying cause of the disease in patients with epidermolysis bullosa simplex (the most common form of the disease), and (ii) to treat the major symptoms of the disease in all patients with EB.
InMed’s initial pre-clinical studies were focused on studying the potential of INM-750 to treat the cause of the disease by modulating the expression of the various keratins that are critical to maintaining the integrity of the skin. We have previously reported that InMed has been able to demonstrate that certain phytocannabinoids are able to positively influence the expression of the key keratins K5, K6, K14, K15 and K16. We continue to make progress in studying the effect of different cannabinoids at different doses on keratin expression, and a summary of our initial results are now available on our website.

Click here to read the full InMed Pharmaceuticals (OTCMKTS:IMLFF) press release.